Literature DB >> 3312850

Symposium on antimicrobial agents. The quinolones.

R C Walker1, A J Wright.   

Abstract

The fluoroquinolones are a new class of antimicrobial agents structurally related to nalidixic acid. They have a broad spectrum of activity against pathogens, including Pseudomonas aeruginosa, other multiresistant gram-negative bacteria, and methicillin-resistant Staphylococcus aureus but not anaerobes. They are well absorbed after oral administration, and some achieve serum and tissue levels well exceeding the minimal inhibitory concentrations for susceptible bacteria. Adverse reactions are rare, and when they occur they are usually mild. Use of quinolones should be avoided in children because of possible damage to developing cartilage. These agents should prove useful in the treatment of urinary tract infections caused by bacteria resistant to other oral agents, bacterial gastroenteritis, and gonococcal infections. The use of quinolones may potentially reduce the cost of treatment of certain systemic infections caused by multiantimicrobial resistant organisms because outpatient oral therapy is possible.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312850     DOI: 10.1016/s0025-6196(12)65073-3

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  7 in total

1.  In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.

Authors:  D Gargallo-Viola; M Esteve; S Llovera; X Roca; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

Authors:  D Gargallo-Viola; M Esteve; M Moros; R Coll; M A Xicota; C de Andres; R Roser; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

3.  Clinical and chemical interactions between iron preparations and ciprofloxacin.

Authors:  M Kara; B B Hasinoff; D W McKay; N R Campbell
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

4.  Effect of enrofloxacin on digoxin clearance and steady-state serum concentrations in dogs.

Authors:  M J Novotny; D H Shaw
Journal:  Can J Vet Res       Date:  1991-04       Impact factor: 1.310

5.  Comparative activities of eight quinolones against members of the Bacteroides fragilis group.

Authors:  M V Borobio; M Conejo; E Ramirez; A I Suarez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

6.  Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae.

Authors:  T Mazzulli; A E Simor; R Jaeger; S Fuller; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

7.  In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone.

Authors:  J Fung-Tomc; J V Desiderio; Y H Tsai; G Warr; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.